Half-Dose Rivaroxaban versus Antiplatelet Therapy for Preventing Silent Cerebral Embolic Lesions after Left Atrial Appendage Occlusion: The HALO-SCE Trial

Authors, Journal, Affiliations, Type, DOI

Overview

HALO-SCE randomized 164 patients with atrial fibrillation who had successful LAAO confirmed at 45 days — no device-related thrombus and no peri-device leak ≥3 mm — to half-dose rivaroxaban 10 mg daily or antiplatelet therapy. Serial diffusion-weighted MRI and cognitive testing over 12 months showed new silent cerebral embolic lesions in 12.2% with rivaroxaban versus 31.7% with antiplatelet therapy (P=0.005). Cognitive scores diverged progressively in favour of rivaroxaban, with 12-month MMSE and MoCA differences of 2.56 and 2.67 points. The composite of death, clinical thromboembolism and major bleeding was numerically lower with rivaroxaban (2.4% versus 11.0%; P=0.057), while major bleeding occurred in none of the rivaroxaban patients and 3.7% of the antiplatelet group. The trial is small and exploratory for clinical endpoints but directly challenges the common practice of switching to antiplatelet therapy after LAAO.

Keywords

Left atrial appendage occlusion, atrial fibrillation, half-dose rivaroxaban, antiplatelet therapy, silent cerebral embolic lesions, diffusion-weighted MRI, cognitive function, Watchman, randomized controlled trial

Key Takeaways

Background and Rationale

Methods

Participants

Primary Imaging Outcome

Cognitive Outcomes

Clinical Outcomes and Adherence

Interpretation

Limitations of the Document

Key Concepts Mentioned

Key Entities Mentioned

Wiki Pages Updated